A double-blind, placebo-controlled, randomized study to evaluate the weight gain drug, mirtazapine transdermal ointment, in cats with unintended weight loss.

Abstract

Mirtazapine is classified as a weight gain drug in cats, and the purpose of this study was to evaluate its efficacy in cats experiencing unintended weight loss. This was a multi-center, double-blind, placebo-controlled, randomized clinical study in client-owned cats &#x2265;1&#xa0;year of age, weighing &#x2265;2&#xa0;kg, with a documented loss (&#x2265;5%) in body weight. Cats were treated once daily with either 2&#xa0;mg/cat mirtazapine transdermal ointment (n&#xa0;=&#xa0;83) or placebo (n&#xa0;=&#xa0;94) (Per Protocol population) applied to the inner surface of the pinna for 14&#xa0;&#xb1;&#xa0;3&#xa0;days. Physical examination, body weight, complete blood count, serum chemistry, and urinalysis were performed prior to treatment and on Day 14. Changes in body weight between the mirtazapine and placebo groups were evaluated from Day 1 to Day 14 and compared using a two-sample t test. The mean percent change in body weight was +3.9% (standard deviation &#xb1;5.4%) in the mirtazapine group and +0.4% (&#xb1;3.3%) in the placebo group (p&#xa0;<&#xa0;0.0001). The most common adverse event was mild erythema at the application site in 17.4% of placebo and 10.4% of mirtazapine-treated cats. Application of mirtazapine transdermal ointment was well tolerated both topically and systemically and resulted in significant weight gain in cats experiencing unintended weight loss associated with various underlying diseases.